THERAPY-DRIVEN EVOLUTION AND INTRATUMORAL GENETIC HETEROGENEITY IN CNS LYMPHOMAS. Read more about THERAPY-DRIVEN EVOLUTION AND INTRATUMORAL GENETIC HETEROGENEITY IN CNS LYMPHOMAS.
THE TOLL-LIKE RECEPTOR 7/8 PATHWAY HAS PROGNOSTIC SIGNIFICANCE AND IS A THERAPEUTIC TARGET IN CNS LYMPHOMAS. Read more about THE TOLL-LIKE RECEPTOR 7/8 PATHWAY HAS PROGNOSTIC SIGNIFICANCE AND IS A THERAPEUTIC TARGET IN CNS LYMPHOMAS.
Reducing the risks of nuclear war-The role of health professionals. Read more about Reducing the risks of nuclear war-The role of health professionals.
IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY-DIAGNOSED PRIMARY CNS LYMPHOMA. Read more about IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY-DIAGNOSED PRIMARY CNS LYMPHOMA.
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models. Read more about BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models.
PHASE II/III STUDY OF R-MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS. Read more about PHASE II/III STUDY OF R-MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Read more about Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL. Read more about Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL.
CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA. Read more about CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA.
